ST Pharm (237690) Stock Outlook 2026: The Oligonucleotide CDMO Riding the RNA Drug Wave

ST Pharm Is, Ultimately, a Capacity-Cycle Story

Here is the first thing I tell anyone looking at ST Pharm. This is not a biotech betting the company on one clinical readout. It sells picks and shovels to the RNA-therapeutics gold rush. The old line about the merchants who sold jeans and pickaxes outearning most of the miners fits this name unusually well.

My read up front: ST Pharm’s stock is driven less by drug trial data and more by the timing of capacity expansion and utilization. In a market where RNA-drug demand is exploding, the company that laid down capacity ahead of the curve wins, and the speed at which that capacity fills sets the direction of the shares. Build ahead of demand and get the timing wrong, and depreciation plus fixed costs grind down margins until orders arrive. If you do not hold both faces of that coin in your head at once, you will not hold this stock well.

For a US investor building international exposure, that profile is worth understanding. Most small pharma names are essentially binary clinical bets. ST Pharm instead supplies the raw material for already-commercialized global drugs and books real revenue today — a growth story with actual substance behind it. It carries its own CDMO-specific risks, which I get into below, but the revenue is real.

👉 For a contrast in business model within the same Korean biopharma space, read the Hanall Biopharma (009420) stock outlook alongside this one — the difference in how each makes money is instructive.

---

What an Oligonucleotide CDMO Actually Is

Start with the substance. An oligonucleotide is a short single strand of DNA or RNA. Using these strands to silence or modulate the expression of a disease-causing gene — antisense, siRNA — is the basis of RNA therapeutics, a modality wholly different from small molecules or antibodies.

The hard part is making this material at scale and at pharmaceutical purity. Oligonucleotide synthesis is a chain of dozens of sequential chemical reactions, and the yield and purification of each step dictate final purity. The number of facilities that can reliably deliver kilogram-to-ton commercial batches is small enough to count on your fingers. ST Pharm is one of them.

The strength of the CDMO model is clear. Without taking the drug-development gamble itself, the company earns money supplying raw material no matter which client’s drug succeeds. Spread across many pipelines at many global pharma companies, one failure does not sink the portfolio. That is the whole point of the picks-and-shovels framing.

Dimension	Drug-developing biotech	ST Pharm (oligonucleotide CDMO)
When revenue appears	After trial success and approval (distant)	On client clinical and commercial orders (now)
Failure risk	Value collapses on trial failure	Diversified across many client pipelines
Barrier to entry	Candidate molecule and data	Large-scale synthesis, purity know-how, regulatory track record
Earnings volatility	Event-driven (milestones)	Lumpy revenue tied to order timing

---

Is RNA-Drug Demand Real, or Just a Theme?

The bull case for ST Pharm ultimately rests on one question. Is the RNA-therapeutics market genuinely growing? My judgment: this is structural growth, not a passing theme.

The emblematic case is the cholesterol siRNA drug inclisiran (marketed as Leqvio). Dosed just twice a year, it reshaped chronic-disease management, and as prescriptions grow the oligonucleotide raw-material demand scales into tons. Nusinersen (Spinraza) for spinal muscular atrophy and givosiran for acute hepatic porphyria are already commercial, and the clinical-stage oligonucleotide pipeline runs into the hundreds.

This is the crux. ST Pharm’s addressable market is not “the drugs selling today” but “the entire pipeline that will commercialize.” When a Phase 2 or 3 candidate wins approval, the raw-material order jumps an order of magnitude, from clinical kilograms to commercial tons. That is why ST Pharm effectively treats its clients’ trial progress as a leading indicator of its own growth.

The GLP-1 connection belongs here too. Today’s obesity and diabetes market is dominated by GLP-1 peptides, which do not directly overlap with oligonucleotides. But as metabolic-disease drug development heats up, demand for next-generation oral and RNA-based candidates and for lipid materials rises with it, broadening the base of CDMO capacity demand. Do not read “GLP-1 beneficiary” as direct revenue — but the metabolic drug boom expanding the whole contract-manufacturing pie is real.

---

The Expansion Cycle: The Heart of the Name

The single most important concept in owning ST Pharm is the expansion cycle. It has sequentially built dedicated oligonucleotide production buildings at its Banwol site, and the timing of those investment decisions governs the next several years of results.

Walk through the mechanism stage by stage.

Phase	What happens	Margin impact
Decision and construction	Large capex outlay	No revenue yet, cash outflow
Early operation of new building	Depreciation and fixed costs, low utilization	Margin pressure (possible disappointment window)
Orders fill in	Large-drug commercial volume absorbs capacity	Utilization rises, margin leverage kicks in
Full utilization	Fixed costs diluted across large revenue	Peak margins, next expansion considered

The key point: the moment utilization crosses breakeven, profit inflects non-linearly. This is a fixed-cost-heavy plant business, so once capacity starts filling, much of each incremental revenue dollar drops to profit. Conversely, in the “air pocket” right after a build — when demand recognition lags — depreciation alone rises and you get a loss or a sharp earnings drop.

That is why ST Pharm shares often move on the expectation of “when will utilization fill?” before the reported numbers confirm it. The recurring pattern: undervalued in the disappointment window, then re-rated as a major client drug reaches commercial scale and capacity fills quickly. Reading where you sit in that cycle is the skill.

---

The Dong-A Socio Shield, and Its Limits

ST Pharm sits within the Dong-A Socio group, topped by Dong-A Socio Holdings. That structure carries a few defensive implications.

First, a stable controlling shareholder means low risk of control disputes or abrupt ownership swings. Second, group-level capital and R&D infrastructure let it push large expansions and drug programs that a cash-strapped small biotech would have to abandon. Third, collaboration with pharma affiliates can supplement its drug-development capability.

Do not overrate the affiliate premium, though. Having a group behind it guarantees neither CDMO wins nor drug success. ST Pharm’s valuation still has to be earned by the global competitiveness of its oligonucleotide CDMO and by actual utilization. Group stability supports the floor; only operating results build the ceiling.

👉 For another lens on a Korean pharma franchise’s governance and cash flow, the Boryung (003850) stock outlook shows how differently a group-affiliated drugmaker can be built.

---

A Risk Check to Balance the Optimism

The growth story is attractive, but the risks below deserve honest weight.

Customer and product concentration is the biggest. If a large share of revenue leans on a few major drugs, then a single prescription slowdown, a competing molecule, or an inventory adjustment can swing results hard. The CDMO’s portfolio diversification helps, but in periods with heavy reliance on one blockbuster volume, this risk is very much live.

Expansion timing mismatch. As stressed above, building ahead of demand eats margins during the utilization gap. If capacity that management built on an optimistic demand view fills slower than expected, earnings can disappoint for several quarters.

Lumpy results and market misreading. Quarterly revenue swings with order timing, and if the market reads one weak quarter as structural deterioration, the stock overreacts. The reverse happens too — a one-off large order mistaken for a trend can drive an overheat. That volatility is itself a risk.

Competition and internalization. If global rivals like Nitto Denko or Agilent expand capacity aggressively, price competition follows. Longer term, large pharma moving to internalize supply of critical raw materials threatens CDMO volume.

Currency. With a high export mix, results track the won-dollar rate. A stronger won is a headwind to reported won revenue; a weaker won is a tailwind. For a US-based holder, the currency layer cuts the other way through the dollar-won cross.

Pipeline clinical risk. The in-house drugs (oncology, HIV) offer royalty upside on success, but clinical failure is inherently likely. Price too much drug value into the shares in advance and a trial disappointment cuts deep. I prefer to treat the in-house pipeline conservatively, as a free option.

---

Positioning for a US Investor: Three Scenarios

Scenario 1: A Satellite Growth Position

ST Pharm occupies an unusual seat — a biotech growth name with actual substance. Lower volatility than a binary-trial biotech, but not as steady as big pharma. I would size it as a satellite in an international healthcare sleeve, kept modest.

The key is adjusting exposure to where you are in the expansion cycle. Accumulating in the disappointment window of a newly opened building, then holding into the phase where utilization fills and margin leverage appears, suits this name’s character. Track the order backlog and client-drug momentum rather than reacting to any single quarter.

👉 To frame this within a broader growth-stock strategy, the AI stocks investment guide 2026 widens the lens beyond a single biopharma name.

Scenario 2: Sizing Foreign Exposure and Currency

Because 237690 is a Korean listing, a US investor is taking on won-denominated exposure on top of the equity risk. When the won weakens against the dollar, your dollar return erodes even if the shares rise in won terms; a stronger won amplifies gains. Before adding the position, decide whether you want that currency layer or would rather hedge it.

I always separate the two questions: is this a good business at a fair price, and do I want the won exposure right now? Conflating them is how investors talk themselves into or out of a good company for the wrong reason. Treat the operating thesis and the FX view as two distinct decisions.

👉 For how capital-gains treatment shapes after-tax outcomes on equity holdings, see the stock capital gains tax guide 2026.

Scenario 3: Metric-Linked Monitoring

ST Pharm suits a metric-linked approach better than blind dollar-cost averaging. I would track the signals below and adjust weight accordingly.

• Is utilization of the new oligonucleotide building inflecting up? A sign margin leverage is near — consider adding.
• Are key client drugs (inclisiran and peers) accelerating in prescriptions and sales? A leading signal for rising raw-material orders.
• Is the order backlog trending up? Improving visibility on future revenue.
• Is expansion capex running ahead of demand recognition? A check on air-pocket risk.

The best risk-reward window is when these line up favorably at once. When capacity has grown but utilization stalls and backlog flattens, stepping back is the right call no matter how hot the RNA theme runs.

---

Comparing the Modality and Peers

Set ST Pharm beside biotech names of different character and its positioning sharpens.

Type	Business character	Revenue structure	Key variable
ST Pharm	Oligonucleotide CDMO (raw material)	Order-based revenue + utilization leverage	Expansion timing, client drug commercialization
Drug-developing biotech	Own pipeline	Milestones and royalties on success	Clinical success probability
Large pharma	Finished-drug sales	Steady revenue and dividend	Patent cliff, pipeline
Contract finished-drug CMO	Outsourced finished production	Volume-based	Orders and utilization

The table reveals the seat. None of the explosive upside of a trial-stage biotech, but little of the failure risk; not the stability of big pharma, but more growth. That middle ground — substantive growth — is the identity of this name. So treat it as a growth satellite, neither a pure defensive nor a pure gamble.

👉 To balance it against a dividend-defensive anchor, the SCHD dividend ETF guide 2026 is a useful counterweight.

---

Metrics to Watch Every Quarter

If you own or track ST Pharm, deciding in advance what to read first makes the calls far cleaner.

First, the oligonucleotide CDMO revenue mix and growth rate. Whether the oligonucleotide business is a growing share of total revenue, with growth holding or accelerating, separates a real story from a themed one. Watch whether oligo is offsetting any weakness in small-molecule and other lines.

Second, utilization of the new oligonucleotide building. Whether the added capacity is actually filling decides the margin direction. Once utilization crosses breakeven and rises, profit improves non-linearly.

Third, the order backlog. A leading indicator of revenue visibility. A rising backlog lets you sit through the next few quarters with more confidence.

Fourth, key client drugs’ market performance. When a major client drug like inclisiran grows in prescriptions and sales, raw-material orders follow. It is another company’s number, but it leads ST Pharm’s.

Read together, these move you past the “revenue grew X percent” headline to the real question — how fast expansion capex is converting into profit.

---

Related Reading

• 👉 Hanall Biopharma (009420) Stock Outlook 2026: Autoimmune Drugs and the Royalty Model
• 👉 Boryung (003850) Stock Outlook 2026: The Kanarb Franchise and the LBA Strategy
• 👉 AI Stocks Investment Guide 2026: Core Names and ETF Selection
• 👉 Stock Capital Gains Tax Guide 2026: After-Tax Strategy in Practice

---

This article is for informational purposes and reflects an investment opinion; it is not a recommendation to buy or sell any security. Equity investing carries the risk of loss of principal, and investment decisions should be made on your own judgment considering your financial situation and risk tolerance. Any business status or outlook described here reflects the time of writing; always verify the latest disclosures and professional advice before investing.